Similar results were obtained with drug selected cancer cells that acquired ABCG2-mediated resistance to mitoxantrone, such as H460/MX20 and S1-M1-80, overexpressing wild-type and 482-G mutant ABCG2, respectively. This evidence concerns the gene ABCG2 and cancer.